Produktname:Benzoyl chloride, 2-fluoro-6-methyl- (9CI)
IUPAC Name:2-fluoro-6-methylbenzoyl chloride
- CAS:535961-78-5
- Molekulare Formel:C8H6ClFO
- Reinheit:95%+
- Katalognummer:CM329672
- Molekulargewicht:172.58
Nur für den Einsatz in Forschung und Entwicklung..
Produkt-Details
- CAS-Nr.:535961-78-5
- Molekulare Formel:C8H6ClFO
- Schmelzpunkt:-
- SMILES-Code:O=C(Cl)C1=C(C)C=CC=C1F
- Dichte:
- Katalognummer:CM329672
- Molekulargewicht:172.58
- Siedepunkt:
- Mdl-Nr.:
- Lagerung:
Category Infos
- Benzenes
- Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.
Column Infos
- Zegocractin
- CalciMedica announces positive topline data from phase 2b CARPO trial of Auxora™ in Acute Pancreatitis (AP). The trial met primary objective with statistically significant dose response. Calcium release–activated calcium (CRAC) channels are involved in activating T cells, and responsible for regulating calcium-dependent inflammatory pathways or tissue cell injury pathways. AP is a potentially life-threatening inflammatory disease of the pancreas featured by aberrant signaling of calcium.
CalciMedica’s Auxora is a potent and selective intravenous formulated CRAC channel inhibitor containing the active ingredient Zegocractin. It is being developed for the treatment of acute inflammatory and immunologic illnesses, including severe AP, AIPT, AKI, and severe acute respiratory diseases including AHRF, and ARDS.